By Nikki Kean
After the recent recall of angiotensin II receptor blockers (ARBs), the FDA released further information about how nitrosamine impurities may affect the public and how many patients have been affected.
AUGUST 28, 2019
AUGUST 28, 2019
By Nikki Kean
After the recent recall of angiotensin II receptor blockers (ARBs), the FDA released further information about how nitrosamine impurities may affect the public and how many patients have been affected.